NIKKEI 225
39,680.08 +506.93 (+1.29%) HANG SENG
18,069.75 -3.15 (-0.02%) CRUDE OIL
81.22 +0.39 (+0.48%) GOLD FUTURES
2,327.80 -3.00 (-0.13%) DOW
39,112.16 -299.05 (-0.76%) Bitcoin GBP
48,689.77 +388.55 (+0.80%)
GLUE Jul 2024 7.500 put
| Previous close | 5.0000 |
| Open | N/A |
| Bid | 1.1500 |
| Ask | 3.5000 |
| Strike | 7.50 |
| Expiry date | 2024-07-19 |
| Day's range | 5.0000 - 5.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 48 |
GlobeNewswireMonte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initial clinical data expected in Q1 2025 Poster presentation today at 14:45 CET / 8:45 a.m. ET BOSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel mole
Simply Wall St.Institutional investors own a significant stake of 40% in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)
Key Insights Institutions' substantial holdings in Monte Rosa Therapeutics implies that they have significant influence...
- GlobeNewswire
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 3:30 p.m. ET. A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at
